Home › Research › Risk genes beyond APOE
The role of mitochondria in Alzheimer's disease
Lou Delphine Muenger. Zenodo (CERN European Organization for Nuclear Research), 2026-03-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This diploma thesis presents the work carried out during 6 months within the Laboratory directed by Professor Millet, written under the supervision and with the support of Dr. Benjamin Tournier and Silvia Braconi Quintaje. The aim of this work is participation in research to elucidate the role of mitochondria in Alzheimer’s disease. Two main proteins are studied: the 18 kDa translocator protein (TSPO) and the mitochondrial pyruvate carrier 1 (MPC1), they are part of two projects named TIADI for TSPO and Martinou2 for MPC1.In this work, the expression mechanisms of various proteins and genes in an animal model of Alzheimer’s disease (3xTgAD mice) are studied. Several proteins of interest will be quantified and analyzed. The proteins and RNA analyzed are the amyloid precursor protein hAPP encoded by the gene APP. The glial fibrillary acidic protein (GFAP) is expressed by astrocytes and encoded by the gene GFAP. The Ionized calcium-binding adapter molecule (IBA1) a protein expressed by microglia, encoded by the gene IBA1. The 18 kDa translocator protein (TSPO), a neuroinflammation protein expressed by glial and endothelial cells.Aβ40 and 42 soluble and insoluble will also be quantified, they are involved in the physiology of the human body and in Alzheimer’s disease forAβ42.Aβ total and Tau will be analyzed. The amyloid degradation enzymes will be quantified, namely insulin degrading enzyme (IDE) and Apolipoprotein E (ApoE). Finally, cell culture will allow to provide another model for the study of mitochondria and of ATP. The appendices contain all protocols and a list of abbreviations to facilitate reading. Keywords: Alzheimer, Aβ, Tau, Mitochondria, TSPO, MPC1, ATP, GFAP, IBA1
What this study adds
Evidence grade: Low
This is a diploma thesis describing planned work in an animal model of Alzheimer's disease, so it does not yet report any treatment or cure. It aims to study the role of mitochondria and proteins such as TSPO and MPC1, but no findings on treating or preventing Alzheimer's are given.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Muenger, L. D. (2026). The role of mitochondria in Alzheimer's disease. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.19226924
Vancouver
Muenger LD. The role of mitochondria in Alzheimer's disease. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.19226924.
BibTeX
@article{muenger2026-96fd3c60,
author = {Muenger, Lou Delphine},
title = {{The role of mitochondria in Alzheimer's disease}},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
doi = {10.5281/zenodo.19226924},
url = {https://doi.org/10.5281/zenodo.19226924}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The 18 kDa translocator protein (TSPO), a neuroinflammation protein expressed by glial and endothelial cells.Aβ40 and 42 soluble and insoluble will also be quantified, they are involved in the physiology of the human body and in Alzheimer’s disease forAβ42.Aβ total and Tau will be analyzed.
- The amyloid degradation enzymes will be quantified, namely insulin degrading enzyme (IDE) and Apolipoprotein E (ApoE).
- Finally, cell culture will allow to provide another model for the study of mitochondria and of ATP.
- The appendices contain all protocols and a list of abbreviations to facilitate reading.
- Keywords: Alzheimer, Aβ, Tau, Mitochondria, TSPO, MPC1, ATP, GFAP, IBA1
Why it matters
This is a diploma thesis describing planned work in an animal model of Alzheimer's disease, so it does not yet report any treatment or cure. It aims to study the role of mitochondria and proteins such as TSPO and MPC1, but no findings on treating or preventing Alzheimer's are given.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 29/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, senior author's track record and institution's track record, so those were left out: it earned 26 of the 89 points we could judge it on, which is 29 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Zenodo (CERN European Organization for Nuclear Research)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Lou Delphine Muenger holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 89 | Scored on 17 of 20 parts. We have no data for the rest, so they are left out: 26 of the 89 points we could judge it on is 29 out of 100. |
| Total | 29 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.5281/zenodo.19226924
- Original source →
- Free full text: Zenodo (CERN European Organization for Nuclear Research) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Risk genes beyond APOE from nearby years
Also in Risk genes beyond APOE
105 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.